,TAFHBsAg

Kazuto Tajiri1, Yuka Hayashi1, Aiko Murayama1

  • 1Third Department of Internal Medicine, Faculty of Medicine, Academic Assembly, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan.

Viruses
|January 25, 2025
PubMed
概括

在某些慢性乙型肝炎患者中,切换为诺福维尔胺胺 (TAF) 可能会降低乙型肝炎表面抗原 (HBsAg),特别是那些基线HBsAg水平较低和轻度纤维化患者. 在这项研究中,TAF耐受性很好.